Mild DOCA-salt hypertension: Sympathetic system and role of renal nerves

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 5, 2011, Pages

  Kandlikar, Sachin S ^a   Fink, Gregory D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Renal denervation; Whole body norepinephrine spillover

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; NORADRENALIN; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DIASTOLIC BLOOD PRESSURE; HEART RATE; HYPERTENSION; KIDNEY DENERVATION; KIDNEY NERVE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; HYPERTENSION; KIDNEY; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 79955763168     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00972.2010     Document Type: Article

References (58)

1. Berecek KH, Bohr DF. Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig. Circ Res 42: 764-771, 1978.
2. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38: 1107-1111, 2001.
3. Bouvier M, de Champlain J. Increased apparent norepinephrine release rate in anesthetized DOCA-salt hypertensive rats. Clin Exp Hypertens A 7: 1629-1645, 1985.
4. Cabral AM, Silva IF, Gardioli CR, Mauad H, Vasquez EC. Diverse effects of renal denervation on ventricular hypertrophy and blood pressure in DOCA-salt hypertensive rats. Braz J Med Biol Res 31: 587-590, 1998.
5. Damase-Michel C, Tavernier G, Llau ME, Chollet F, Senard JM, Bagheri H, Tran MA, Houin G, Guiraud-Chaumeil B, Montastruc JL. [Is there any desensitization of presynaptic alpha2-adrenergic receptors in hypertension? Experimental and clinical studies.] Arch Mal Coeur Vaiss 85: 1149-1151, 1992.
6. Damase-Michel C, Tran MA, Llau ME, Chollet F, Senard JM, Guiraud-Chaumeil B, Montastruc JL, Montastruc P. The effect of yohimbine on sympathetic responsiveness in essential hypertension. Eur J Clin Pharmacol 44: 199-201, 1993.
7. de Champlain J, Bouvier M, Drolet G. Abnormal regulation of the sympathoadrenal system in deoxycorticosterone acetate-salt hypertensive rats. Can J Physiol Pharmacol 65: 1605-1614, 1987.
8. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 77: 75-197, 1997.
9. Dzielak DJ, Norman RA Jr. Renal nerves are not necessary for onset or maintenance of DOC-salt hypertension in rats. Am J Physiol Heart Circ Physiol 249: H945-H949, 1985.
10. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91: 35-62, 2001.
11. Eisenhofer G. Sympathetic nerve function-assessment by radioisotope dilution analysis. Clin Auton Res 15: 264-283, 2005.
12. Eisenhofer G, McCarty R, Pacak K, Russ H, Schomig E. Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn Schmiedebergs Arch Pharmacol 354: 287-294, 1996.
13. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNFalpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76-R83, 2008.
14. Esler M, Jackman G, Bobik A, Leonard P, Kelleher D, Skews H, Jennings G, Korner P. Norepinephrine kinetics in essential hypertension. Defective neuronal uptake of norepinephrine in some patients. Hypertension 3: 149-156, 1981.
15. Esler M, Leonard P, Kelleher D, Jackman G, Bobik A, Skews H, Jennings G, Korner P. Assessment of neuronal uptake of noradrenaline in humans: defective uptake in some patients with essential hypertension. Clin Exp Pharmacol Physiol 7: 535-539, 1980.
16. Esler M. Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol 108: 227-237, 2010.
17. Fink GD, Johnson RJ, Galligan JJ. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension. Hypertension 35: 464-469, 2000.
18. Fujita K, Matsumura Y, Kita S, Miyazaki Y, Hisaki K, Takaoka M, Morimoto S. Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol 114: 925-930, 1995.
19. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 36: 300-309, 1975.
20. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 54: 690-697, 2009.
21. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 17: 719-734, 1999.
22. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 7: 335-346, 2006.
23. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 653: 131-138, 1994.
24. Iriuchijima J, Mizogami S, Sokabe H. Sympathetic nervous activity in renal and DOC hypertensive rats. Jpn Heart J 16: 36-43, 1975.
25. Jacob F, Clark LA, Guzman PA, Osborn JW. Role of renal nerves in development of hypertension in DOCA-salt model in rats: a telemetric approach. Am J Physiol Heart Circ Physiol 289: H1519-H1529, 2005.
26. Jadhav A, Torlakovic E, Ndisang JF. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 296: F521-F534, 2009.
27. Katholi RE, Naftilan AJ, Bishop SP, Oparil S. Role of the renal nerves in the maintenance of DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion. Hypertension 5: 427-435, 1983.
28. Katholi RE, Naftilan AJ, Oparil S. Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. Hypertension 2: 266-273, 1980.
29. Katholi RE, Winternitz SR, Oparil S. Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 69: 55-62, 1982.
30. Katholi RE, Winternitz SR, Oparil S. Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat. Clin Exp Hypertens A 4: 707-716, 1982.
31. Keeton TK, Biediger AM. The measurement of norepinephrine clearance and spillover rate into plasma in conscious spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 338: 350-360, 1988.
32. King AJ, Novotny M, Swain GM, Fink GD. Whole body norepinephrine kinetics in ANG II-salt hypertension in the rat. Am J Physiol Regul Integr Comp Physiol 294: R1262-R1267, 2008.
33. Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab 95: 4756-4761, 2010.
34. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275-1281, 2009.
35. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337-362, 1980.
36. Loch D, Hoey A, Brown L. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat. Clin Exp Hypertens 28: 475-488, 2006.
37. Luo M, Fink GD, Lookingland KJ, Morris JA, Galligan JJ. Impaired function of alpha2-adrenergic autoreceptors on sympathetic nerves associated with mesenteric arteries and veins in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol 286: H1558-H1564, 2004.
38. Luo M, Hess MC, Fink GD, Olson LK, Rogers J, Kreulen DL, Dai X, Galligan JJ. Differential alterations in sympathetic neurotransmission in mesenteric arteries and veins in DOCA-salt hypertensive rats. Auton Neurosci 104: 47-57, 2003.
39. May CN. Differential regional haemodynamic changes during mineralocorticoid hypertension. J Hypertens 24: 1137-1146, 2006.
40. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 17: 1057-1062, 1991.
41. Moreau P, Drolet G, Yamaguchi N, de Champlain J. Alteration of prejunctional alpha2-adrenergic autoinhibition in DOCA-salt hypertension. Am J Hypertens 8: 287-293, 1995.
42. O'Donaughy TL, Brooks VL. Deoxycorticosterone acetate-salt rats: hypertension and sympathoexcitation driven by increased NaCl levels. Hypertension 47: 680-685, 2006.
43. Osborn JW, Fink GD. Region-specific changes in sympathetic nerve activity in angiotensin II-salt hypertension. Exp Physiol 95: 61-68, 2010.
44. Pirpiris M, Cox H, Esler M, Jennings GL, Whitworth JA. Mineralocorticoid induced hypertension and noradrenaline spillover in man. Clin Exp Hypertens 16: 147-161, 1994.
45. Provoost AP, De Jong W. Differential development of renal, DOCA-salt, and spontaneous hypertension in the rat after neonatal sympathectomy. Clin Exp Hypertens 1: 177-189, 1978.
46. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Endothelin-1 gene expression and vascular hypertrophy in DOCA-salt hypertension compared to spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22: S188-S190, 1995.
47. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43: 169-175, 2004.
48. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361
49. Takahashi H, Iyoda I, Yamasaki H, Takeda K, Okajima H, Sasaki S, Yoshimura M, Nakagawa M, Ijichi H. Retardation of the development of hypertension in DOCA-salt rats by renal denervation. Jpn Circ J 48: 567-574, 1984.
50. Takata Y, Yamashita Y, Takishita S, Fujishima M. Vasopressin and sympathetic nervous functions both contribute to development and maintenance of hypertension in DOCA-salt rats. Clin Exp Hypertens A 10: 203-227, 1988.
51. Titze J, Bauer K, Schafflhuber M, Dietsch P, Lang R, Schwind KH, Luft FC, Eckardt KU, Hilgers KF. Internal sodium balance in DOCAsalt rats: a body composition study. Am J Physiol Renal Physiol 289: F793-F802, 2005.
52. Trostel KA, Osborn JW. Do renal nerves chronically influence renal function and arterial pressure in spinal rats? Am J Physiol Regul Integr Comp Physiol 263: R1265-R1270, 1992.
53. Tsuda K, Tsuda S, Nishio I, Masuyama Y. Inhibition of norepinephrine release by presynaptic alpha2-adrenoceptors in mesenteric vasculature preparations from chronic DOCA-salt hypertensive rats. Jpn Heart J 30: 231-239, 1989.
54. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 13: 113-122, 1995.
55. Xu H, Bian X, Watts SW, Hlavacova A. Activation of vascular BK channel by tempol in DOCA-salt hypertensive rats. Hypertension 46: 1154-1162, 2005.
56. Xu H, Fink GD, Galligan JJ. Increased sympathetic venoconstriction and reactivity to norepinephrine in mesenteric veins in anesthetized DOCAsalt hypertensive rats. Am J Physiol Heart Circ Physiol 293: H160-H168, 2007.
57. Yemane H, Busauskas M, Burris SK, Knuepfer MM. Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. Exp Physiol 95: 51-55, 2009.
58. Zugck C, Lossnitzer D, Backs J, Kristen A, Kinscherf R, Haass M. Increased cardiac norepinephrine release in spontaneously hypertensive rats: role of presynaptic alpha-2A adrenoceptors. J Hypertens 21: 1363-1369, 2003.